New, non-invasive prostate cancer test beats PSA in detecting prostate cancer, researchers report. Simple urine test leads to more accurate diagnoses, fewer false-positive results. – An experimental biomarker test developed by researchers at the University of Michigan more accurately detects prostate cancer than any other screening method currently in use, according to a study published in the February 1 issue of Cancer Research, a journal of the American Association for Cancer Research.
Interim analysis supports continuation of Cell Genesys’ VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer – Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.
Five genetic variants and a family history accounted for almost half (46 percent) of prostate cancer patients. Researchers identified five genetic locations associated with risk of developing prostate cancer: three on chromosome 8q24, one on chromosome 17q12 and one on 17q24.3. – Genetic testing of DNA in a blood sample can determine which men are likely to develop prostate cancer, as five genetic variants previously associated with prostate cancer risk have a strong cumulative effect.
World Health Organization study found that night shift work increases the risk of cancer in humans. Women are at a higher risk to develop breast and colon cancer and men more likely to experience prostate cancer.
– A study by the World Health Organization has found that night shift work increases the risk of cancer in humans. The study found that after prolonged exposure to night shift work, women are at a higher risk to develop breast and colon cancer. Men who work the night shift are more likely to experience prostate cancer.